Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection

Chiasma's Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to abnormal enlargement of patients' extremities and internal organs, the drugmaker said.